Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00324-2/abstract?utm_campaign=update-lanres&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanres&_hsenc=p2ANqtz-_gBmTdXk_9uHKBtb8vgFgxpgR6a77A5EpkQAhfcsnBGj6Zm9NqFJaEjk7f1jrqcUPk2UuADstb9Z7P_-wOSpSaBhQdvw&_hsmi=343282117&utm_content=343275138&utm_source=hs_email